L iver disease is one of the leading causes of death among individuals who are infected with human immunodeficiency virus (HIV). (1) Advances in direct-acting antiviral and antiretroviral therapies have helped reduce the risk of liver-related and acquired immune deficiency syndrome (AIDS)-related adverse outcomes, respectively, among individuals infected with hepatitis C virus (HCV) and HIV. (2) Consequently, extrahepatic non-AIDSrelated complications, particularly cardiovascular disease, now represent an increasingly important proportion of morbidity and mortality risk in these populations. (3, 4) Understanding traditional and novel mechanisms driving these complications is essential to quantifying and minimizing their risk among chronic HCV-infected, HIV-infected, and other populations at risk for liver disease.
Several plausible mechanisms connect liver disease and cardiovascular disease. For example, cirrhosis contributes to the development of hyperdynamic circulation, electrophysiologic abnormalities, and systolic and diastolic dysfunction in a syndrome termed cirrhotic cardiomyopathy. (5) Cirrhosis is also associated with altered synthesis of coagulant and anticoagulant factors that could lead to thrombosis or hemorrhage, (6) thereby increasing ischemic heart disease risk. Bacterial translocation from the intestinal lumen to extraintestinal sites is common among people with cirrhosis (7) and is associated with immune system activation and inflammation, (8) which further drive atherosclerosis and ischemic heart disease and ultimately result in congestive heart failure (CHF). (9) Congestive hepatopathy occurs when heart failure leads to increased systemic venous pressure, hepatocyte atrophy, and perisinusoidal edema, which drive hypoperfusion and hypoxia in hepatocytes. (10) The mechanisms connecting liver and cardiovascular diseases are bidirectional such that liver disease may cause heart disease and heart disease may cause liver disease. (5) This study was designed to focus on the former mechanism-liver disease leading to heart disease-and minimize potential confounding by the latter mechanism. Specifically, we sought to examine whether subclinical liver disease (stages of liver fibrosis) assessed noninvasively would be associated with incident CHF events. Elucidating the mechanisms of CHF risk is important because heart disease is among the 10 leading causes of death in the general population (11) and a growing cause for concern among aging HIV-infected individuals. (12, 13) Liver fibrosis is potentially reversible (14) and can be measured noninvasively using routine clinical laboratory tests, such as fibrosis 4 index (FIB-4) score. (15) If liver fibrosis is associated with incident CHF events, this could have implications for research and clinical practice. First, it would improve our understanding of the mechanisms driving excess cardiovascular disease risk in the setting of HIV infection. Second, it may prompt clinicians to screen for CHF among HIV-infected and -uninfected patients who are at risk for liver fibrosis or liver fibrosis progression.
Our primary hypothesis is that increasing liver fibrosis, as determined by FIB-4, (15) is independently associated with incident CHF events accounting for Framingham and other established cardiovascular disease risk factors. We assessed whether this association is modified by HIV or HCV status. We tested this hypothesis in the Veterans Aging Cohort Study (VACS), a longitudinal prospective cohort of HIVinfected veterans matched for age, race/ethnicity, and clinical site with two uninfected veterans in care.
ARTICLE INFORMATION:

Patients and Methods
DATA SOURCE
Participants were selected from the VACS, which has been described previously. (16) VACS participants have been continuously enrolled each year since 1998 using a validated existing algorithm from the US Department of Veterans Affairs (VA) national electronic medical record system. Institutional review boards at Yale University, West Haven VA Medical Center, and Vanderbilt University approved this study.
STUDY PARTICIPANTS
All participants who were alive and enrolled in VACS on or after April 1, 2003, were eligible for the study. Participants were excluded if they had prevalent cardiovascular disease based on International Classification of Diseases, Ninth Revision (ICD-9) codes for CHF, cardiomyopathy, acute myocardial infarction (AMI), unstable angina, coronary artery revascularization, ischemic stroke, or hemorrhagic stroke. (13, (17) (18) (19) Prevalent cardiovascular disease included events occurring up to 6 months after baseline. Data on prevalent cardiovascular disease included ICD-9 diagnoses from Veterans Health Administration electronic health records, Medicare, Medicaid, and VA fee-for-service records. VA fee-for-service represents care provided to veterans who receive care outside the VA health care system that is not covered by Medicare.
Baseline was defined as a patient's first clinical encounter on or after April 1, 2003 , and follow-up ended after an incident CHF event (see dependent variables), death, last follow-up date, or December 31, 2011.
DEPENDENT VARIABLE
The outcome was time to first CHF event defined using ICD-9 diagnoses (402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 428.xx). At least one inpatient or two outpatient codes on different days were required for a CHF event to be confirmed. ICD-9 data were obtained from VA electronic health records, Medicare, and VA fee-forservice records.
INDEPENDENT VARIABLES
The primary exposure was three mutually exclusive liver fibrosis categories defined by FIB-4 score. FIB-4 is calculated as the product of age (years) and aspartate aminotransferase (U/L) divided by the product of platelet count (10 9 /L) and the square root of alanine aminotransferase (U/L). The categories were FIB-4 < 1.45 (from here referred to as minimal fibrosis), FIB-4 1.45-3.25 (moderate fibrosis), and FIB-4 > 3.25 (advanced fibrosis/cirrhosis). Those with missing FIB-4 data were included a fourth category for descriptive analyses and subsequently imputed as described below. In HIV-and HCV-infected populations, FIB-4 3.25 correctly identifies advanced hepatic fibrosis 71% of the time (i.e., positive predictive value [sensitivity 31%, specificity 93%]). FIB-4 1.45 correctly rules out advanced fibrosis 83% of the time (i.e., negative predictive value [sensitivity 73%, specificity 70%]). (20) Previous work among HIV/ HCV-uninfected populations with nonalcoholic fatty liver disease (NAFLD) showed that FIB-4 > 3.25 had a positive predictive value of 53% (sensitivity 48%, specificity 95%) for advanced fibrosis; for FIB-4 < 1.45, the negative predictive value was 98% (sensitivity 90%, specificity 64%). (21) Alanine aminotransferase levels, aspartate aminotransferase levels, and platelet counts were obtained from VA laboratory records before and up to 180 days after baseline.
COVARIATES
Covariate data closest to baseline date were used. Sociodemographic data included age, sex, and race/ ethnicity. Framingham cardiovascular disease risk factors-including diabetes, hypertension, and total and high-density lipoprotein cholesterol-were measured using electronic health record data. (13) Diabetes was diagnosed using glucose measurements, use of insulin or oral hypoglycemic agents, and/or at least one inpatient and/or two outpatient ICD-9 codes, as validated previously. (22) Hypertension was defined as systolic blood pressure greater than 140 mm Hg or use of antihypertensive medication. (23) Lipid levels were categorized based on National Cholesterol Education Program Adult Treatment Panel III criteria. (24) Smoking was measured from the VA Health Factors data repository. (25) Smoking was categorized into current, past, and never smoking. Body mass index was dichotomized at 30 kg/m 2 with values at or above this threshold indicating obesity. Antecedent incident AMI (i.e., an AMI that was not present at baseline, but occurred during follow-up prior to the CHF event) was defined using the inpatient 410 ICD-9 code.
HIV infection was present if a participant had at least one inpatient and/or two outpatient ICD-9 codes for HIV infection. (16) HCV infection was defined as a positive HCV antibody or RNA test or at least one inpatient and/or two outpatient ICD-9 codes for this diagnosis. (26) We also collected data on HIV-1 RNA, CD4 1 T-lymphocyte counts (CD4 cell counts), and current use of antiretroviral therapy (ART). We included all ART medications that were on VA formulary during the study period. We have previously shown in a nested sample that 98% of HIV-infected Veterans on ART obtain their medications from the VA. (16) HIV-1 RNA, CD4 cell counts, and antiretroviral therapy data were obtained from VA laboratory and pharmacy records before and up to 180 days after baseline.
History of cocaine or alcohol abuse or dependence was defined using ICD-9 codes. (27) 
STATISTICAL ANALYSIS
Descriptive statistics for all variables by FIB-4 category were assessed using the Kruskal-Wallis test for continuous variables and chi-square test for categorical variables. We calculated rates of CHF per 1000 person-years stratified by FIB-4 categories. We further assessed CHF rates and risk across FIB-4 categories stratified by HIV/HCV status. We calculated mortality rates stratified by FIB-4 categories to enable us to assess the potential competing risk of death with elevated FIB-4 occurring before a CHF event. (28) All variables had complete data except the following: LDL cholesterol data (n 5 74,559), HDL cholesterol (n 5 75,543), triglycerides (n 5 76,046), SBP (n 5 92,961), smoking (n 5 65,118), BMI (n 5 91,534), CD4T count (n 5 25,327), and HIV-1 RNA (n 5 26,048). P values across FIB-4 groups (excluding missing FIB-4 group) were all < 0.01. Abbreviations: BP, blood pressure; HDL, high-density lipoprotein; HIV1, HIV-infected; LDL, low-density lipoprotein.
We examined the association between FIB-4 and incident CHF using six Cox proportional hazard models: 1) unadjusted; 2) adjusted for age and race/ethnicity; 3) adjusted for Framingham 30-year cardiovascular disease risk factors (age, treated or untreated systolic blood pressure, smoking, diabetes, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides) plus race/ethnicity; 4) adjusted for model 2 covariates plus antecedent incident acute myocardial infarction; 5) adjusted for model 3 covariates plus HIV and HCV status; and 6) adjusted for covariates in model 5 plus body mass index and history of substance use (alcohol dependence/abuse, cocaine). We repeated the sixth model stratifying by HIV/HCV status instead of adjusting for it.
Sensitivity analyses were conducted to minimize confounding factors and the impact of reverse causality on our results. First, we excluded participants with conditions at baseline that are likely to drive liver fibrosis and/or are associated with CHF: diabetes, alcohol abuse/dependence, HCV, and obesity. Second, we assessed incident CHF events occurring at least 2 years (as opposed to 6 months in the primary analysis) after baseline FIB-4 measurement. This further increased separation between FIB-4 measurement and incident CHF, making it more likely that our results would reflect the effect of liver fibrosis on CHF and not vice versa (i.e., reverse causality by congestive hepatopathy). Congestive hepatopathy occurs when heart failure (often right-sided) leads to increased venous pressure, including in the hepatic veins and sinusoids, which could ultimately lead to hepatocellular injury and liver enzyme and FIB-4 alterations. (10, 29, 30) Third, we excluded participants with hepatic decompensation (31) before incident CHF diagnosis or censoring. This was done to further minimize reverse causality by congestive hepatopathy. Hepatic decompensation was defined based on previously validated ICD-9 diagnoses of ascites, portal hypertension, spontaneous bacterial peritonitis, and/or esophageal variceal hemorrhage, (31) which are relevant features in congestive hepatopathy. (32, 33) Regression models were run using multiple imputation techniques that generated five datasets with complete covariate values. (34) Relative risk estimates using imputed data were consistent with those from the missing category analyses. Regression results presented are based on imputed datasets.
Results
After excluding individuals with preexisting cardiovascular disease, the 96,373 people free of cardiovascular disease at baseline were included in these analyses.
In this cohort of HIV-infected and -uninfected veterans, 59% of patients (n 5 57,309) had minimal fibrosis, 17% (n 5 16,360) had moderate fibrosis, and 4% (n 5 3679) had advanced fibrosis/cirrhosis. Compared with those with minimal fibrosis, participants with advanced fibrosis/cirrhosis were more likely to be older and have HIV or HCV (Table 1) . Those with advanced fibrosis/cirrhosis were less likely to be female or white. Participants with advanced fibrosis/ cirrhosis had a greater prevalence of diabetes, current smoking, and alcohol or cocaine abuse/dependence, but lower total cholesterol and body mass index (Table 1) .
Those missing FIB-4 (n 5 19,025) were similar to participants with minimal fibrosis. Overall, compared with those with an available FIB-4 score, participants with missing FIB-4 scores had a lower prevalence of HIV infection, HCV, diabetes, hypertension, highdensity lipoprotein cholesterol < 40 mg/dL, and current smoking (Table 1) .
Over a median of 6.9 (interquartile range, 3.2-8.6) years of follow-up, there were 3844 incident CHF events. Elevated FIB-4 was associated with increasing rates of incident CHF despite competing risk of higher mortality among participants with higher FIB-4 scores (Figure 1 Table 2 ). The pattern of increasing risk of CHF with increasing FIB-4 score remained when the analyses were stratified by HIV and HCV status ( Table 3 ). The association of advanced fibrosis/cirrhosis and incident CHF persisted regardless of HIV/HCV status ( Table 3 ). The association of moderate fibrosis and incident CHF remained statistically significant only among participants with either HIV or HCV infection ( 
Discussion
In this study, higher FIB-4 scores, including those indicative of moderate liver fibrosis, were significantly associated with an increased risk of incident CHF. The association between FIB-4 and incident CHF was present even after adjustment for traditional cardiovascular disease risk factors and antecedent AMI, regardless of HIV/HCV status, and despite increased total mortality among participants with higher FIB-4 scores.
Previous studies examining associations between liver disease and incident cardiovascular disease events focused on the etiologies of the underlying liver disease (e.g., viral hepatitis, obesity leading to fatty liver disease) and not severity of hepatic fibrosis (i.e., minimal, moderate or advanced fibrosis/cirrhosis, as measured by FIB-4 score). (35) (36) (37) (38) This focus on etiology does not address whether the extent of hepatic fibrosis is an important determinant of CHF risk. Our cohort is large, has a high proportion of non-whites, and includes people without diabetes, which extends generalizability beyond previous studies. (39) (40) (41) (42) Further extending previous work, (40, 41, 43, 44) our analyses also accounted for alcohol dependence/abuse, HIV, and HCV as well as other comorbid conditions linked to liver fibrosis such as obesity and smoking.
This large study reports that moderate liver fibrosis is associated with 17% increased risk of CHF after adjustment for possible confounders. Importantly, participants with prevalent cardiovascular disease were excluded from the analysis, and only the first occurrence of CHF was considered. This methodology minimized the possibility of reverse causality due to congestive hepatopathy (i.e., finding a significant association that reflects the effect of heart disease on the liver rather than the effect of liver disease on the heart). (5) Moreover, results from sensitivity analyses excluding patients who developed hepatic decompensation before an incident CHF event or censoring were consistent with those of the primary analyses. Clinical features of hepatic decompensation overlap with features of congestive hepatopathy; thus, by eliminating hepatic decompensation, we further minimize the likelihood of reverse causality due to congestive hepatopathy. Adjusting for antecedent AMI did not alter the association between FIB-4 and incident CHF, suggesting that this association is independent of AMI events occurring before CHF diagnosis. The association of advanced liver fibrosis/cirrhosis with increased CHF risk persisted among participants without HIV and HCV, suggesting an association that is independent of HIV and HCV. Our findings are also consistent with a previous study using data from the National Health and Nutrition Examination Survey that reported increased risk of cardiovascular mortality associated with higher NAFLD fibrosis scores. (45) Taken together, these data provide evidence that the etiology (e.g., NAFLD), type, and severity (e.g., moderate fibrosis) of liver disease contribute to cardiovascular disease risk.
The mechanisms driving the association between FIB-4 score and incident CHF are understudied, particularly in relation to intermediate levels of liver fibrosis. Earlier work reports an association between cirrhosis and hyperdynamic circulation, electrophysiologic abnormalities, and systolic and diastolic dysfunction that culminate in cirrhotic cardiomyopathy. (5) It may be that similar hemodynamic and electrophysiologic alterations are occurring, albeit to a lesser extent in individuals who have not yet progressed to cirrhosis, and contributing over time to increased risk of clinical CHF. Whether improving liver health reduces the risk of future CHF warrants further study. These results may have important implications for health care providers. Although clinicians are very familiar with traditional CHF risk factors such as diabetes, understanding that even moderate liver fibrosis may independently contribute to the increased risk of heart failure may be important for reducing the risk of heart failure events. The fact that vulnerable populations-such as individuals infected with HIV, HCV, or both-already have an increased risk of cardiovascular disease events, makes assessing liver health a potentially important part of any cardiovascular disease risk reduction strategy in these groups. FIB-4 score is calculated using routinely available clinical laboratory results. Therefore, clinicians could incorporate FIB-4 assessment into their heart failure risk stratification procedures and prioritize interventions to improve liver health (e.g., alcohol use reduction, weight loss, glycemic control, successful treatment of HCV, viral suppression of HIV) as appropriate.
LIMITATIONS
This study has important limitations that merit discussion. First, CHF outcomes were not adjudicated. However, we did use validated ICD-9 codes that have been used previously. Moreover, these ICD-9 codes were obtained from multiple data sources (i.e., VA, Medicare, and VA fee-for-service data), thus minimizing the possibility of missing CHF events that occurred outside the VA health care system. (17) Second, although the FIB-4 score was originally developed among HIV/HCV-coinfected individuals with clinically diagnosed liver disease that called for liver biopsy, subsequent studies have assessed this measure in several other populations, including HCV-uninfected individuals and others without an indication for liver biopsy. (46) (47) (48) These studies suggest that FIB4 score can be used as an accurate indication of liver fibrosis in a cohort such as the VACS. Third, although FIB-4 score is considered an acceptable surrogate marker of liver fibrosis, there are noninvasive measures (e.g., FibroScan, magnetic resonance elastography, enhanced liver fibrosis score) and invasive measures (i.e., liver biopsy) that may better discriminate stages of liver fibrosis. However, these other fibrosis measures are not routinely collected on all patients within a health care system and, in the case of liver biopsy, have a risk/benefit ratio that may be unacceptable for patients who are at low risk for liver fibrosis. (49) Fourth, the associations between FIB-4 and incident CHF could have been attributable to reverse causality by congestive hepatopathy; however, we excluded individuals with prevalent cardiovascular disease up to 2 years after FIB-4 measurement; analyzed only the first occurrence of new heart failure; and found similar results after exclusions of individuals with a diagnosis of hepatic decompensation before incident CHF diagnosis or censoring. Fifth, only baseline values of FIB-4 used in analyses and thus we cannot comment on changes in liver health during the follow-up period. Sixth, only baseline covariates were used in analyses, thus we cannot comment on whether changes in covariates (e.g., hepatitis status) explain some or all of the association of FIB-4 with CHF risk. Seventh, the population was predominantly male, so these findings may not generalize to women. Finally, as with all observational studies, there is potential for unmeasured confounding.
SUMMARY
In conclusion, participants with moderate and severe liver fibrosis/cirrhosis as measured by FIB-4 score had an increased risk of CHF compared with participants with no liver fibrosis. This association persisted even among participants who did not have hepatitis C and or HIV infection. Moreover, this increased risk of CHF was present even though participants with moderate and severe liver fibrosis had significantly higher mortality rates than those without liver fibrosis. The results suggest that assessing liver health may be important for reducing the risk of future CHF events, particularly among HIV-and HCV-infected individuals in whom cardiovascular disease risk is elevated and liver disease is common.
